专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

61. 发明申请

US20210206851A1 LAG-3-Binding Molecules and Methods of Use Thereof 有权
公开(公告)号：US20210206851A1
公开(公告)日：2021-07-08
申请号：US17147279
申请日：2021-01-12
申请人： MacroGenics, Inc.
发明人： Ross La Motte-Mohs , Kalpana Shah , Douglas H. Smith , Leslie S. Johnson , Paul A. Moore , Ezio Bonvini , Scott Koenig
IPC分类号： C07K16/28 , A61P31/04
摘要： The present invention is directed to the anti-LAG-3 antibodies: LAG-3 mAb 1, LAG-3 mAb 2, LAG-3 mAb 4, LAG-3 mAb 5, and LAG-3 mAb 6, and to humanized and chimeric versions of such antibodies. The invention additionally pertains to LAG-3-binding molecules that comprise LAG-3 binding fragments of such anti-LAG-3 antibodies, immunoconjugates, and to bispecific molecules, including diabodies, BiTEs, bispecific antibodies, etc., that comprise (i) such LAG-3-binding fragments, and (ii) a domain capable of binding an epitope of a molecule involved in regulating an immune check point present on the surface of an immune cell. The present invention also pertains to methods of detecting LAG-3, as well as methods of using molecules that bind LAG-3 for stimulating immune responses.

62. 发明授权

US10961311B2 B7-H3 binding molecules, antibody drug conjugates thereof and methods of use thereof 有权
公开(公告)号：US10961311B2
公开(公告)日：2021-03-30
申请号：US16092740
申请日：2017-04-13
申请人： MacroGenics, Inc.
发明人： Deryk T. Loo , Ling Huang , Leslie S. Johnson , Thomas Son , Juniper A. Scribner , Ezio Bonvini
IPC分类号： C07K16/28 , A61K47/68 , A61K39/395 , A61P35/00 , A61K39/00
摘要： The present invention is directed to novel B7-H3-binding molecules capable of binding to human and non-human B7-H3, and in particular to such molecules that are cross-reactive with B7-H3 of a non-human primate (e.g., a cynomolgus monkey). The invention additionally pertains to B7-H3-binding molecules that comprise Variable Light Chain and/or Variable Heavy Chain (VH) Domains that have been humanized and/or deimmunized so as to exhibit a reduced immunogenicity upon administration to recipient subjects. The invention particularly pertains to bispecific, trispecific or multispecific B7-H3-binding molecules, including bispecific diabodies, BiTEs, bispecific antibodies, trivalent binding molecules, etc. that comprise: (i) such B7-H3-binding Variable Domains and (ii) a domain capable of binding to an epitope of a molecule present on the surface of an effector cell. The invention is also directed to pharmaceutical compositions that contain any of such B7-H3-binding molecules, and to methods involving the use of any of such B7-H3-binding molecules in the treatment of cancer and other diseases and conditions. The invention also particularly pertains to a molecule that comprises the human B7-H3 binding domain of a humanized anti-human B7-H3 antibody conjugated to at least one drug moiety (a “B7-H3-ADC”). The invention is also directed to pharmaceutical compositions that contain such B7-H3-ADCs, and to methods involving the use of any of such B7-H3-ADCs in the treatment of cancer and other diseases and conditions.

63. 发明申请

US20210054065A1 COMPOUND TARGETING IL-23A AND TNF-ALPHA AND USES THEREOF 有权
公开(公告)号：US20210054065A1
公开(公告)日：2021-02-25
申请号：US17002890
申请日：2020-08-26
申请人： BOEHRINGER INGELHEIM INTERNATIONAL GMBH , MACROGENICS, INC.
发明人： Rachel Rebecca Barrett , Leslie S. Johnson , Sanjaya Singh , Kathleen Last-Barney , Daw-Tsun Shih , Patricia Giblin , Scott Brodeur , Nelamangala Nagaraja
IPC分类号： C07K16/24
摘要： The disclosure relates to compounds specific for IL23A and TNF-alpha, compositions comprising the compounds, and methods of use thereof. Nucleic acids, cells, and methods of production related to the compounds and compositions are also disclosed.

64. 发明申请

US20210047426A1 Bi-Specific Monovalent Diabodies That are Capable of Binding CD123 and CD3, and Uses Thereof 有权
公开(公告)号：US20210047426A1
公开(公告)日：2021-02-18
申请号：US17000447
申请日：2020-08-24
申请人： MacroGenics, Inc.
发明人： Ezio Bonvini , Leslie S. Johnson , Ling Huang , Paul A. Moore , Gurunadh Reddy Chichili , Ralph Froman Alderson
IPC分类号： C07K16/28
摘要： The present invention is directed to sequence-optimized CD123×CD3 bi-specific monovalent diabodies that are capable of simultaneous binding to CD123 and CD3, and to the uses of such diabodies in the treatment of hematologic malignancies.

65. 发明授权

US10793629B2 Compound targeting IL-23A and TNF-alpha and uses thereof 有权
公开(公告)号：US10793629B2
公开(公告)日：2020-10-06
申请号：US16052133
申请日：2018-08-01
申请人： BOEHRINGER INGELHEIM INTERNATIONAL GMBH , MACROGENICS, INC.
发明人： Rachel Rebecca Barrett , Leslie S. Johnson , Sanjaya Singh , Kathleen Last-Barney , Daw-Tsun Shih , Patricia Giblin , Scott Brodeur , Nelamangala Nagaraja
IPC分类号： C12N15/63 , A61K39/395 , C07K16/24 , G01N33/574 , C12P15/00 , C12N5/0783 , A61K39/00 , C12N5/07
摘要： The disclosure relates to compounds specific for IL23A and TNF-alpha, compositions comprising the compounds, and methods of use thereof. Nucleic acids, cells, and methods of production related to the compounds and compositions are also disclosed.

66. 发明授权

US10787521B2 Bi-specific monovalent diabodies that are capable of binding CD123 and CD3, and uses thereof 有权
公开(公告)号：US10787521B2
公开(公告)日：2020-09-29
申请号：US15730868
申请日：2017-10-12
申请人： MacroGenics, Inc.
发明人： Ezio Bonvini , Leslie S. Johnson , Ling Huang , Paul A. Moore , Gurunadh Reddy Chichili , Ralph Froman Alderson
IPC分类号： C07K16/28 , A61K39/00
摘要： The present invention is directed to sequence-optimized CD123×CD3 bi-specific monovalent diabodies that are capable of simultaneous binding to CD123 and CD3, and to the uses of such diabodies in the treatment of hematologic malignancies.

67. 发明授权

US10647768B2 Multi-chain polypeptide-containing tri-specific binding molecules 有权
公开(公告)号：US10647768B2
公开(公告)日：2020-05-12
申请号：US15313741
申请日：2015-05-29
申请人： MacroGenics, Inc.
发明人： Leslie S. Johnson , Ling Huang , Gurunadh Reddy Chichili , Kalpana Shah , Chia-Ying Kao Lam , Stephen James Burke , Liqin Liu , Paul A. Moore , Ezio Bonvini , Bhaswati Barat
IPC分类号： C07K16/28 , C07K16/30
摘要： The present invention relates to Tri-Specific Binding Molecules, which are multi-chain polypeptide molecules that possess three Binding Domains and are thus capable of mediating coordinated binding to three epitopes. The Binding Domains may be selected such that the Tri-Specific Binding Molecules are capable of binding to any three different epitopes. Such epitopes may be epitopes of the same antigen or epitopes of two or three different antigens. In a preferred embodiment, one of such epitopes will be capable of binding to CD3, the second of such epitopes will be capable of binding to CD8, and the third of such epitopes will be capable of binding to an epitope of a Disease-Associated Antigen. The invention also provides a novel ROR1-binding antibody, as well as derivatives thereof and uses for such compositions.

68. 发明申请

US20190270813A1 Bi-Specific Monovalent Fc Diabodies That Are Capable of Binding CD32B and CD79b and Uses Thereof 审中-公开
公开(公告)号：US20190270813A1
公开(公告)日：2019-09-05
申请号：US16412839
申请日：2019-05-15
申请人： MacroGenics, Inc.
发明人： Leslie S. Johnson , Ling Huang , Kalpana Shah , Ezio Bonvini , Paul A. Moore , Wei Chen
IPC分类号： C07K16/28 , C07K16/46
摘要： The present invention is directed to bi-specific monovalent diabodies that comprise an immunoglobulin Fc Domain (“bi-specific monovalent Fc diabodies”) and are composed of three polypeptide chains and which possess at least one binding site specific for an epitope of CD32B and one binding site specific for an epitope of CD79b (i.e., a “CD32B×CD79b bi-specific monovalent Fc diabody”). The bi-specific monovalent Fc diabodies of the present invention are capable of simultaneous binding to CD32B and CD79b. The invention is directed to such compositions, to pharmaceutical compositions that contain such bi-specific monovalent Fc diabodies and to methods for their use in the treatment of inflammatory diseases or conditions, and in particular, systemic lupus erythematosus (SLE) and graft vs. host disease.

69. 发明授权

US10280231B2 Compound targeting IL-23A and B-cell activating factor (BAFF) and uses thereof 有权
公开(公告)号：US10280231B2
公开(公告)日：2019-05-07
申请号：US15215690
申请日：2016-07-21
申请人： Boehringer Ingelheim International GmbH , MacroGenics, Inc.
发明人： Sanjaya Singh , Qi Pan , Rachel Rebecca Barrett , Leslie S. Johnson , Pankaj Gupta , Sarah Low , Haixia Wu
IPC分类号： C07K16/46 , A61K39/395 , C07K16/24 , C07K16/28 , A61K39/00
摘要： The disclosure relates to compounds specific for IL23A and BAFF, compositions comprising the compounds, and methods of use thereof. Nucleic acids, cells, and methods of production related to the compounds and compositions are also disclosed.

70. 发明申请

US20180371104A1 Deimmunized Serum-Binding Domains and Their Use in Extending Serum Half-Life 审中-公开
公开(公告)号：US20180371104A1
公开(公告)日：2018-12-27
申请号：US15946034
申请日：2018-04-05
申请人： MacroGenics, Inc.
发明人： Ezio Bonvini , Bhaswati Barat , Ling Huang , Leslie S. Johnson
IPC分类号： C07K16/32 , C07K16/28 , C07K16/44 , C07K14/315
摘要： The present invention is directed to a polypeptide (for example, an antigen-binding molecule) that comprises a polypeptide portion of a deimmunized serum-binding protein capable of binding to said serum protein. The presence of the serum-binding protein extends the serum half-life of the polypeptide, relative to the serum half-life of the polypeptide if lacking the polypeptide portion of the deimmunized serum-binding protein. The invention also pertains to methods and uses that employ such molecules.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式